Homepage > Company > Media > Pharma News > 2019 > Roche buys U.S. drugmaker Promedior for up to $1.4 billion to get lung drug

Roche buys U.S. drugmaker Promedior for up to $1.4 billion to get lung drug

ZURICH (Reuters) - Swiss drugmaker Roche is paying up to $1.4 billion to buy U.S. biotech company Promedior, whose main drug candidate against the lung disease idiopathic pulmonary fibrosis is set to begin late-stage trials, Promedior said on Friday.

The deal includes a payment of $390 million, plus the potential for $1 billion more if conditions are met. Promedior’s lead asset PRM-151 is being studied in IPF where the firm said it helped improve lung function, on top of current therapies.

Roche already has an IPF medicine, Esbriet, with 2018 sales of just over $1 billion.

NOVEMBER 15, 2019

https://www.reuters.com/

Read also

Alembic Pharma rises on USFDA approval for Rivaroxaban Tablets

Alembic Pharmaceuticals advanced 1.10% to Rs 918.15 after the company received final approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (A...

GSK to spend $2bn on Phase III liver disease drug acquisition

Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals’ efimosfermin, a drug ready to hit Phase III trials for the treatment of...

Amneal Receives U.S. FDA Approval for Brekiya®

Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults

Preclinical + European Hematology Association 2025 Congress

Rgenta Therapeutics Announces Presentation of Preclinical Data from Lead Program, RGT-61159, a Potent and Selective Small Molecule Inhibitor of MYB RNA, at the European Hematology Association (EHA...